Please login to the form below

Not currently logged in
Email:
Password:

UK signals desire for close post-Brexit relationship with EU

Health and business ministers outline areas where collaboration may continue

Brexit

The UK government appears to be ready to take a more pragmatic stance on its post-Brexit approach to medicines regulation.

Writing in the Financial Times, health secretary Jeremy Hunt and business secretary Greg Clark said “the UK would like to find a way to continue to collaborate with the EU”.

Such a deal would both be “in the interests of public health and safety” and help protect the UK’s pharmaceutical industry, they added.

Although not yet official policy, it’s the clearest signal yet of the UK’s Brexit negotiating position as it concerns the pharmaceutical industry, and found praise from the sector.

ABPI chief executive Mike Thompson said: "This letter is a welcome recognition that the future of medicines regulation is a key priority for the government as we negotiate a new relationship with the EU.

"It also signals a readiness to take a pragmatic approach to Brexit negotiations that puts people’s health first. This is a great first step and we look forward to seeing more detail in the coming weeks and months.”

Regardless of the UK’s eventual pharma position, the EMA has been busy scenario planning on the assumption the country will no longer participate in its work or the European medicines regulatory system after 30 March 2019.

Before then location of the EMA after it leaves London is set to be decided in November this year, with the industry keen for a swift decision on the issue.

Article by
Dominic Tyer

4th July 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics